Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Journal article

Open access

Peer reviewed

B.J. Monk, T.J. Herzog, S. Triantos, S. Maul, G. Wang, M J Pontes Valero, T. McGowan, W.S. Shalaby and R.L. Coleman

Annals of oncology, Vol.30, pp.v420-v421

10/2019

Files and links (1)

url

https://doi.org/10.1093/annonc/mdz250.038View

Published (Version of record) Open

4 Record Views

Title: Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Creators: B.J. Monk - University of Arizona
T.J. Herzog - University of Cincinnati
S. Triantos - Janssen
S. Maul - Janssen
G. Wang - Janssen
M J Pontes Valero - PharmaMar
T. McGowan - Health Affairs
W.S. Shalaby - Janssen
R.L. Coleman
Publication Details: Annals of oncology, Vol.30, pp.v420-v421
Identifiers: 991005969062802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article